bearish

Biotest AG

Grifols/Biotest: Preference Shareholders at Disadvantage & Grifols's Leverage

281 Views20 Sep 2021 18:56
The deal should succeed and there are no grounds for Grifols to offer more than €37/pref. Price is high, with negative implications for Grifols's leverage. Discount of B shares likely to increase.
Jesus has highlighted this Insight as a Top Pick
SUMMARY
(Sign Up to Access)
Get started on the Smartkarma Research Network with a complimentary Preview Pass to:
  • Unlock all research summaries
  • Follow top, independent analysts
  • Receive personalised alerts and emails
  • Access Briefings, Analytics, and Events

Upgrade anytime to our paid plans for full-length research, real-time analyst discussions, and more.

Join a thriving community of 45,000+ investors, including the top global asset managers managing over $13trn in assets.

or
Already have an account? Sign In Now
Full Insight
(Paid Plans Only, 12-minute read)
Discussions
(Paid Plans Only)
chart-bar
Logo
Top Quartile
Jesus Rodriguez Aguilar
European Event-Driven Analyst
Multi-AssetEvent-Driven
x